Filter
Reset all

Subjects

Content Types

Countries

AID systems

API

Data access

Database access

Database licenses

Data licenses

Data upload

Data upload restrictions

Enhanced publication

Institution responsibility type

Institution type

Keywords

PID systems

Provider types

Quality management

Repository languages

Software

Syndications

Repository types

  • * at the end of a keyword allows wildcard searches
  • " quotes can be used for searching phrases
  • + represents an AND search (default)
  • | represents an OR search
  • - represents a NOT operation
  • ( and ) implies priority
  • ~N after a word specifies the desired edit distance (fuzziness)
  • ~N after a phrase specifies the desired slop amount
  • 1 (current)
Found 6 result(s)
Country
The Health Canada Drug Product Database contains product specific information on drugs approved for use in Canada. The database is managed by Health Canada and includes human pharmaceutical and biological drugs, veterinary drugs and disinfectant products. It contains approximately 15,000 products which companies have notified Health Canada as being marketed.
MassBank of North America (MoNA) is a metadata-centric, auto-curating repository designed for efficient storage and querying of mass spectral records. It intends to serve as a the framework for a centralized, collaborative database of metabolite mass spectra, metadata and associated compounds. MoNA currently contains over 200,000 mass spectral records from experimental and in-silico libraries as well as from user contributions.
Content type(s)
<<<!!!<<< The repository is no longer available. >>>!!!>>>The information is accessible through PubChem:https://pubchem.ncbi.nlm.nih.gov/. Help for HSDB Users in PubChem PDF: https://www.nlm.nih.gov/toxnet/Accessing_HSDB_Content_from_PubChem.pdf Help for HSDB Users in PubChem Web Page: https://www.nlm.nih.gov/toxnet/Accessing_HSDB_Content_from_PubChem.html <<<!!!>>>
The COVID-19 pandemic has affected every country in the world. It is well documented that those most susceptible to the worst outcomes of COVID-19 are the immunocompromised and those with underlying comorbidities. Therefore, patients requiring treatment for COVID-19 will also be on additional medication, posing a risk for drug-drug interactions (DDIs). In order to address this, the Liverpool Drug Interactions website team developed this freely available drug interactions resource to provide information on the likelihood of interactions between the experimental agents used for the treatment of COVID-19 and commonly prescribed co-medications.